Vaccines Market worth $57.8 Billion by 2019

The report “Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019”, the global vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8% from 2014 to 2019.

Browse 145 market data tables and 63 figures spread through 220 pages and in-depth TOC on “Vaccine Market”

Early buyers will receive 10% customization on this report.


The global vaccine technology market involves different human vaccines that help in the prevention and treatment of diseases such as cholera, typhoid, and influenza. Vaccine technology market is driven by several factors which include high prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. The emerging market and increasing vaccine research have opened an array of opportunities for growth of the market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of market.


The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. This market is segmented on the basis of type, technology, disease indication, end user, and geography.


The vaccine technology market by type is divided into preventive and therapeutic vaccines. Preventive vaccines accounted for the largest share of the market primarily due to the increasing prevalence of infectious diseases. In addition, increasing investments by government and non-government organizations to enhance vaccine research and supply doses worldwide will further enhance the growth of market.


Inquiry before Buying:


On the basis of technologies, the vaccines market is classified into live attenuated, toxoid, conjugate, subunit, recombinant vector, inactivated, synthetic, and dendritic cell vaccines. The subunit vaccines segment accounted for the largest share of the market. Increasing research activities for development of more effective and safe vaccines will drive the growth of market.


The disease indication vaccine technology market is segmented into infectious diseases, cancer, and allergy. The infectious diseases segment accounted for a major share of market. Growth in this segment can be attributed to the high prevalence of infectious diseases and increasing government initiatives to improve immunization programs across the globe. The infectious diseases segment is further categorized into pneumococcal, influenza, DTP, hepatitis, rotavirus, and varicella, meningococcal, polio, MMR and others. The cancer segment is classified as cervical cancer and others.


On the basis of end users, the vaccine technology market is segmented into pediatrics and adults. Pediatrics is the major end user of market. High prevalence of diseases such as tuberculosis, mumps, and meningitis will boost the growth of this segment.


You can speak To Research Analyst to know more about Report:


The global market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America will continue to lead the global market in the forecast period. However, Asia is expected to be the fastest-growing market, with growth centered on China, India, and Japan.


Key players in the vaccine technology market include Bavarian Nordic (Denmark), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson and Johnson (U.S.), MedImmune, LLC (U.S.), Merck and Company (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Sanofi Pasteur (France).


Browse Related Reports:

Veterinary Vaccines & Animal Vaccines Market [Products (Livestock - Bovine, Companion - Canine, Poultry, Equine), Diseases (Rabies, Distemper, Foot & Mouth, Gumboro, Avian Influenza, Strangles), Technology (Live attenuated, DNA, Recombinant)] - Global Forecast to 2018


Opportunity Analysis of H1N1 (swine flu) Vaccination Market.


About MarketsandMarkets:

MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.


M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.


We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.


Subscribe Reports from Healthcare Domain @


Mr. Rohan

North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441

Visit MarketsandMarkets Blog @

Connect with us on LinkedIn @